Acumen Pharmaceuticals Q3 2026 Results: Net Loss of $25.4M, Loss Narrows
For the nine months ended September 30, 2026, Acumen Pharmaceuticals reported a net loss of $78.8 million, an improvement from the $96.2 million loss in the prior year period, primarily driven by a decrease in research and development expenses. The company's cash, cash equivalents, and marketable securities totaled $78.6 million as of September 30, 2026, down from $116.9 million at the end of 2025.
- Key figure
- Net loss $25.4M